{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T23:08:10Z","timestamp":1789427290770,"version":"build-2803163510"},"reference-count":58,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"unspecified","delay-in-days":21,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["3332021091"],"award-info":[{"award-number":["3332021091"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018904","name":"Beijing Xisike Clinical Oncology Research Foundation","doi-asserted-by":"publisher","award":["Y-MSDPU2022-0822"],"award-info":[{"award-number":["Y-MSDPU2022-0822"]}],"id":[{"id":"10.13039\/100018904","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Science and Technology Major Project of China","award":["2025ZD01905805"],"award-info":[{"award-number":["2025ZD01905805"]}]},{"name":"Special Program for Basic Resource Survey of the Ministry of Science and Technology","award":["2019FY101101"],"award-info":[{"award-number":["2019FY101101"]}]},{"name":"Beijing Natural Science Foundation","award":["L258061"],"award-info":[{"award-number":["L258061"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82573682"],"award-info":[{"award-number":["82573682"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,4,1]]},"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Neoadjuvant immune checkpoint blockade (ICB) combined with chemotherapy has demonstrated higher response rates than chemotherapy alone in resectable esophageal squamous cell carcinoma (ESCC). Although tumor microenvironment (TME) features associated with treatment response have been studied in the contexts of both chemotherapy and immunotherapy, direct comparisons of these characteristics and their implications for novel therapeutic development remain largely unexplored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Paired pretreatment and post-treatment tumor samples were prospectively collected from 55 patients with locally advanced ESCC enrolled in a multicenter, phase 3 clinical trial (ChiCTR2000040034). Patients were randomized to receive neoadjuvant chemotherapy (paclitaxel with cisplatin, TP; n=14) or its combination with PD-1 blockade (camrelizumab, albumin-bound paclitaxel and cisplatin\/paclitaxel and cisplatin, Cam+nab-TP\/TP; n=41), followed by surgical resection. Pathological response was defined based on Mandard\u2019s Tumor Regression Grade scoring system. Changes in immune cell populations and tumor-associated antigens (TAAs) within the TME in relation to response were characterized using single-cell RNA and T cell receptor sequencing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Both chemotherapy and chemoimmunotherapy responders exhibited shared temporal dynamics including dendritic cell remodeling, cytotoxic CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cell contraction, and memory T cell expansion, with chemoimmunotherapy uniquely suppressing the clonal expansion of GZMB\n                      <jats:sup>+<\/jats:sup>\n                      TIGIT\n                      <jats:sup>+<\/jats:sup>\n                      T cells. In contrast, non-responders failed to elicit effective antitumor immunity and displayed persistent expression of targetable TAAs, fully preserved HLA machinery, and clonal expansion of dysfunctional GZMB\n                      <jats:sup>+<\/jats:sup>\n                      TIGIT\n                      <jats:sup>+<\/jats:sup>\n                      T cells.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our study identifies key immune contributors correlated with response to neoadjuvant therapies and a panel of TAAs in non-responders. These findings support the development of TAA-targeted therapeutic vaccines and combination strategies incorporating ICB to overcome resistance in non-responders.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2025-014562","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T13:40:13Z","timestamp":1776865213000},"page":"e014562","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Single-cell dissection of persistent tumor antigens in non-responders reveals opportunities for TAA-targeted vaccination after neoadjuvant therapy in esophageal squamous cell carcinoma"],"prefix":"10.1136","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct02692976","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04212377","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8892-0930","authenticated-orcid":false,"given":"Ruixiang","family":"Zhang","sequence":"first","affiliation":[{"name":"Section of Esophageal and Mediastinal Oncology, Department of Thoracic Surgery, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6400-9636","authenticated-orcid":false,"given":"Shu","family":"Qi","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Molecular Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhou","sequence":"additional","affiliation":[{"name":"Beijing Immupeutics Medicine Technology Limited, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Hu","sequence":"additional","affiliation":[{"name":"Biomedical Innovation Center, Beijing Key Laboratory for Therapeutic Cancer Vaccines, Beijing Shijitan Hospital, Capital Medical University, Beijing, China"},{"name":"Beijing Cell Therapy Translational Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Li","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Molecular Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Li","sequence":"additional","affiliation":[{"name":"Beijing Immupeutics Medicine Technology Limited, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Qin","sequence":"additional","affiliation":[{"name":"Section of Esophageal and Mediastinal Oncology, Department of Thoracic Surgery, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai-Rong","family":"Yang","sequence":"additional","affiliation":[{"name":"Beijing Immupeutics Medicine Technology Limited, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henghui","family":"Zhang","sequence":"additional","affiliation":[{"name":"Biomedical Innovation Center, Beijing Key Laboratory for Therapeutic Cancer Vaccines, Beijing Shijitan Hospital, Capital Medical University, Beijing, China"},{"name":"Engineering Research Center of Immunocellular Therapy, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihua","family":"Liu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Molecular Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7676-2659","authenticated-orcid":false,"given":"Yin","family":"Li","sequence":"additional","affiliation":[{"name":"Section of Esophageal and Mediastinal Oncology, Department of Thoracic Surgery, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"2026042206400648000_14.4.e014562.1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.03614"},{"key":"2026042206400648000_14.4.e014562.2","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-011-2049-9"},{"key":"2026042206400648000_14.4.e014562.3","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41591-022-02179-2","article-title":"First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial","volume":"29","author":"Song","year":"2023","journal-title":"Nat Med"},{"key":"2026042206400648000_14.4.e014562.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2022.02.007"},{"key":"2026042206400648000_14.4.e014562.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032125"},{"key":"2026042206400648000_14.4.e014562.6","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.12836"},{"key":"2026042206400648000_14.4.e014562.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01234-4"},{"key":"2026042206400648000_14.4.e014562.8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30110-8"},{"key":"2026042206400648000_14.4.e014562.9","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1038\/s41591-024-03064-w","article-title":"Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO\/NCCES01 trial","volume":"30","author":"Qin","year":"2024","journal-title":"Nat Med"},{"key":"2026042206400648000_14.4.e014562.10","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1097\/JS9.0000000000000978","article-title":"Neoadjuvant camrelizumab combined with paclitaxel and nedaplatin for locally advanced esophageal squamous cell carcinoma: a single-arm phase 2 study (cohort study)","volume":"110","author":"Yang","year":"2024","journal-title":"Int J Surg"},{"key":"2026042206400648000_14.4.e014562.11","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004291","article-title":"Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma","volume":"10","author":"Liu","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026042206400648000_14.4.e014562.12","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jncc.2022.04.002","article-title":"Phase Ib trial of camrelizumab combined with chemotherapy and apatinib for neoadjuvant treatment of locally advanced thoracic esophageal squamous cell carcinoma","volume":"2","author":"Wang","year":"2022","journal-title":"Journal of the National Cancer Center"},{"key":"2026042206400648000_14.4.e014562.13","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003497","article-title":"Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma","volume":"10","author":"Yang","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026042206400648000_14.4.e014562.14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.68.1718"},{"key":"2026042206400648000_14.4.e014562.15","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4443"},{"key":"2026042206400648000_14.4.e014562.16","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.101"},{"key":"2026042206400648000_14.4.e014562.17","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-023-00560-y"},{"key":"2026042206400648000_14.4.e014562.18","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0413-z"},{"key":"2026042206400648000_14.4.e014562.19","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2016.107"},{"key":"2026042206400648000_14.4.e014562.20","doi-asserted-by":"crossref","DOI":"10.1126\/science.abe6474","article-title":"Pan-cancer single-cell landscape of tumor-infiltrating T cells","volume":"374","author":"Zheng","year":"2021","journal-title":"Science"},{"key":"2026042206400648000_14.4.e014562.21","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0235-4"},{"key":"2026042206400648000_14.4.e014562.22","doi-asserted-by":"crossref","unstructured":"Sade-Feldman M , Yizhak K , Bjorgaard SL , et al . Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell 2019;176. doi:10.1016\/j.cell.2018.12.034","DOI":"10.1016\/j.cell.2018.12.034"},{"key":"2026042206400648000_14.4.e014562.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.11.043"},{"key":"2026042206400648000_14.4.e014562.24","doi-asserted-by":"crossref","DOI":"10.1186\/s13059-017-1382-0","article-title":"SCANPY: large-scale single-cell gene expression data analysis","volume":"19","author":"Wolf","year":"2018","journal-title":"Genome Biol"},{"key":"2026042206400648000_14.4.e014562.25","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cels.2018.11.005","article-title":"Scrublet: computational identification of cell doublets in single-cell transcriptomic data","volume":"8","author":"Wolock","year":"2019","journal-title":"Cell Syst"},{"key":"2026042206400648000_14.4.e014562.26","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.22139.1","article-title":"scRepertoire: an R-based toolkit for single-cell immune receptor analysis","volume":"9","author":"Borcherding","year":"2020","journal-title":"F1000Res"},{"key":"2026042206400648000_14.4.e014562.27","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-21246-9","article-title":"Inference and analysis of cell-cell communication using CellChat","volume":"12","author":"Jin","year":"2021","journal-title":"Nat Commun"},{"key":"2026042206400648000_14.4.e014562.28","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0694-x"},{"key":"2026042206400648000_14.4.e014562.29","doi-asserted-by":"publisher","DOI":"10.1038\/nri3307"},{"key":"2026042206400648000_14.4.e014562.30","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202204565","article-title":"Single-cell transcriptomic analysis of primary and metastatic tumor ecosystems in esophageal squamous cell carcinoma","volume":"10","author":"Jia","year":"2023","journal-title":"Adv Sci (Weinh)"},{"key":"2026042206400648000_14.4.e014562.31","doi-asserted-by":"publisher","DOI":"10.1517\/14728222.2011.550879"},{"key":"2026042206400648000_14.4.e014562.32","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2209"},{"key":"2026042206400648000_14.4.e014562.33","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-024-00920-9"},{"key":"2026042206400648000_14.4.e014562.34","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1016\/j.ccell.2025.10.008","article-title":"Remodeling of T and endothelial cells during total neoadjuvant therapy in rectal cancer","volume":"43","author":"Gao","year":"2025","journal-title":"Cancer Cell"},{"key":"2026042206400648000_14.4.e014562.35","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00782-x"},{"key":"2026042206400648000_14.4.e014562.36","doi-asserted-by":"crossref","first-page":"5660","DOI":"10.1038\/s41467-025-60827-w","article-title":"Radiation therapy results in preferential tumor antigen-specific lymphodepletion in head and neck cancer","volume":"16","author":"Zenga","year":"2025","journal-title":"Nat Commun"},{"key":"2026042206400648000_14.4.e014562.37","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.ijrobp.2024.04.065","article-title":"Longitudinal assessment of tumor-infiltrating lymphocytes in primary breast cancer following neoadjuvant radiation therapy","volume":"120","author":"Yoneyama","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026042206400648000_14.4.e014562.38","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10388-025-01165-0","article-title":"Preoperative chemoradiotherapy plus pembrolizumab for esophageal squamous cell carcinoma (ACTS-29)","volume":"23","author":"Hong","year":"2026","journal-title":"Esophagus"},{"key":"2026042206400648000_14.4.e014562.39","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000337","article-title":"Consensus guidelines for the definition, detection and interpretation of immunogenic cell death","volume":"8","author":"Galluzzi","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026042206400648000_14.4.e014562.40","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01323-8"},{"key":"2026042206400648000_14.4.e014562.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2022.06.018"},{"key":"2026042206400648000_14.4.e014562.42","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0522-3"},{"key":"2026042206400648000_14.4.e014562.43","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-022-01132-2"},{"key":"2026042206400648000_14.4.e014562.44","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20050915"},{"key":"2026042206400648000_14.4.e014562.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.09.011"},{"key":"2026042206400648000_14.4.e014562.46","doi-asserted-by":"crossref","first-page":"9097","DOI":"10.1038\/s41467-024-52977-0","article-title":"Single-cell sequencing reveals immune features of treatment response to neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma","volume":"15","author":"Yang","year":"2024","journal-title":"Nat Commun"},{"key":"2026042206400648000_14.4.e014562.47","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-018-0007-y"},{"key":"2026042206400648000_14.4.e014562.48","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00574-3"},{"key":"2026042206400648000_14.4.e014562.49","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.11.005"},{"key":"2026042206400648000_14.4.e014562.50","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/s41586-022-04682-5","article-title":"Landscape of helper and regulatory antitumour CD4+ T cells in melanoma","volume":"605","author":"Oliveira","year":"2022","journal-title":"Nature New Biol"},{"key":"2026042206400648000_14.4.e014562.51","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.03.048"},{"key":"2026042206400648000_14.4.e014562.52","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41571-024-00859-1","article-title":"Dendritic cells as orchestrators of anticancer immunity and immunotherapy","volume":"21","author":"Heras-Murillo","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"2026042206400648000_14.4.e014562.53","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.01.004"},{"key":"2026042206400648000_14.4.e014562.54","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aav3942","article-title":"IFN-III is selectively produced by cDC1 and predicts good clinical outcome in breast cancer","volume":"5","author":"Hubert","year":"2020","journal-title":"Sci Immunol"},{"key":"2026042206400648000_14.4.e014562.55","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001813","article-title":"Tumor-infiltrating plasmacytoid dendritic cells are associated with survival in human colon cancer","volume":"9","author":"Kie\u00dfler","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026042206400648000_14.4.e014562.56","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01666-x"},{"key":"2026042206400648000_14.4.e014562.57","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.celrep.2019.12.096","article-title":"Human pDCs are superior to cDC2s in attracting cytolytic lymphocytes in melanoma patients receiving DC vaccination","volume":"30","author":"van Beek","year":"2020","journal-title":"Cell Rep"},{"key":"2026042206400648000_14.4.e014562.58","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1186\/s40425-019-0787-6","article-title":"Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer","volume":"7","author":"Westdorp","year":"2019","journal-title":"j immunotherapy cancer"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-014562","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T13:40:19Z","timestamp":1776865219000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-014562"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":58,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4,22]]},"published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1136\/jitc-2025-014562"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-014562","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]}}}